Follow Ciliatech’s past history and latest exciting developments via the news stories below.
Ciliatech CEO Olivier Benoit travelled to Shanghai, China last week – a country that is a key future target market owing to the disproportionately high prevalence of Angle Closure Glaucoma (an indication which Ciliatech are actively pursuing for their Intercil® Uveal Spacer). He was pleased to collect the ‘Patient Impact
Major event for advancing innovation in eye care gives Ciliatech first-time opportunity to show US ophthalmic audiences potential of treating open and narrow angle glaucoma in supraciliary space with single device Chavanod (near Annecy), France, October 10, 2024 – Ciliatech, an innovative medtech company focusing on the treatment of glaucoma,
Results presented at Ophthalmology Futures European Forum will show: • Sustained IOP (intraocular pressure) control of 8.0mmHg/33% reduction vs baseline • 70% reduction in medication dependance among patients • 68% of patients remain medication-free at three years, with no significant safety reports Ophthalmology Futures Forums, Barcelona, Spain, September 5, 2024
Ciliatech are delighted to announce the appointment of Stephanie C. Jones to the position of Global Vice President, Clinical and Medical A:airs where she will sit on our senior leadership team. Stephanie joins us from Ora Inc (Andover, Massachusetts), a market-leading full service CRO specializing in ophthalmology – most recently
First independent observations, presented by Dr. Leon Au, leading consultant ophthalmology and eye surgeon, during ICGS 2024 in Abu Dhabi, underscore CID’s strong potential as treatment option for glaucoma Substantial IOP lowering effect from stand-alone procedure Surgical placement of suprachoroidal device without penetrating anterior chamber of eye, irrespective of patients’
The following article, originally published by The Ophthalmologist, provides valuable insights into nurturing innovation in glaucoma surgery. Full credit goes to the original author and publication. You can read the original article here. How one ophthalmologist’s decades-long experience led to the invention of an innovative supraciliary device Over the last
By: Philippe Sourdille, MD GLAUCOMA PHYSICIAN MARCH 1, 2024 VOL OPHTHALMOLOGY MANAGEMENT 28, ISSUE MARCH 2024PAGE(S): E1-E3 A new device grows the glaucoma arsenal while potentially preventing endothelial cell loss and inflammation Glaucoma is characterized by optic nerve damage due to elevated intraocular pressure (IOP) and poses a risk of
Sahil joined the Ciliatech senior leadership team in January 2024 as Global Vice President, Glaucoma Sales & Marketing. Sahil brings with him over 25 years of award-winning industry experience in Ophthalmology and specifically in the glaucoma field having worked for some of the largest companies in the industry including Novartis,
Second-generation CID (Cilioscleral Interpositioning Device) makes cilioscleral surgical procedure, which leaves anterior chamber of eye untouched, less invasive and easier to perform. Chavanod (near Annecy), France, December 5, 2023 – Ciliatech, an ophthalmology medtech company developing a new class of implant to treat glaucoma durably, today announces the release of
Primary angle-closure glaucoma (PACG) represents a significant cause of blindness, affecting more than 17 million people worldwide. The different techniques of minimally invasive glaucoma surgery (MIGS) that have been developed for the management of open-angle glaucoma with a gonioscopic ab interno approach, are not applicable in case of a shallow
This site is only for the use of professionals associated with the field of Ophthalmology and is not intended for patients.
